ARCHIVES

NCI Places Hold On Genentech Drug Trials, Citing Disagreement Over Intellectual Property Provisions.

This article is from The Cancer Letter archive.

Vol. 36 No. 09 | March 12, 2010

Download PDF Visit The Full Archive

Related Articles

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

December 25, 2009

ASSIST evaluation finds proven methods help states fight tobacco.

December 5, 2003

Mayo’s Regional Program – Keys To Success Are Service, Communications

December 9, 1977

DCE Board Ok’s New RFA Programs worth $14 Million

June 29, 1990

HHS, MB, OSTP Urge President To Veto Biomedical Research Authorization; Senate Pushes FTE Levels

November 1, 1985

UK’s NICE Set to Deny Payments For Zaltrap In Second-Line Metastatic Colorectal Cancer

June 26, 2013